

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2016

(Rs. lakhs)

	Unaudited					Year ended 31.03.2016
	3 months ended 30.09.16	Preceding 3 months ended 30.06.16	Corresponding 3 months ended 30.09.15	6 months ended 30.09.16	6 months ended 30.09.15	
Income from Operations						
Sales	78286	68521	69995	146807	133444	275302
Other Operating Income	1626	2012	1758	3638	3479	7319
Total Income from Operations	79912	70533	71753	150445	136923	282621
Expenses						
Cost of materials consumed	14204	16117	14747	30321	28290	63216
Purchases of stock-in-trade	17053	21352	21411	38405	39670	73994
Changes in inventories of finished goods, work-in-progress and stock-in-trade	4891	(6039)	(6147)	(1148)	(9953)	(14448)
Total materials consumed	36148	31430	30011	67578	58007	122762
Employee benefits expense	12699	11804	11290	24503	22095	44337
Depreciation and amortisation expense	658	537	533	1195	1025	2478
Other expenses	16991	18264	17642	35255	32898	67846
Total operating expenses	30348	30605	29465	60953	56018	114661
Total expenses	66496	62035	59476	128531	114025	237423
Profit from Operations before Other Income and Exceptional Items	13416	8498	12277	21914	22898	45198
Other Income	1808	2402	3134	4210	7122	12182
Profit before Exceptional Items	15224	10900	15411	26124	30020	57380
Exceptional Items (Net)	16	182	(784)	198	(1023)	231
Profit before tax	15240	11082	14627	26322	28997	57611
Tax Expense	5355	3855	5072	9210	10041	20148
Net Profit	9885	7227	9555	17112	18956	37463
Other comprehensive income, net of income tax						
A. Items that will not be reclassified to profit or loss	(532)	-	-	(532)	-	20
B. Items that will be reclassified to profit or loss	-	-	-	-	-	-
Total other comprehensive income, net of income tax	(532)	-	-	(532)	-	20
Total comprehensive income for the period	9353	7227	9555	16580	18956	37483
Paid-up Equity Share Capital (Face value per share Rs. 10)	8470	8470	8470	8470	8470	8470
Earnings Per Share (EPS) (of Rs. 10 each) (not annualised)						
Basic and diluted EPS (Rs.)	11.7	8.5	11.3	20.2	22.4	44.2

The Standalone Statement of Assets and Liabilities as required under Regulations 33(3)(f) of the Listing Obligations and Disclosure Requirements Regulations, 2015 is as under:

(Rs. lakhs)

Particulars	As at 30.09.2016	As at 31.03.2016
	Unaudited	
ASSETS		
<u>Non-Current Assets</u>		
Property, Plant and Equipment	22001	20404
Capital work-in-progress	38558	26767
Investment property	945	945
Financial Assets		
i. Investments	4767	4767
ii. Loans	1664	1764
iii. Others	26	30
Income-tax assets (net)	14799	15106
Deferred tax assets (net)	10276	9960
Other non-current assets	13170	12933
Total non-current assets	106206	92676
<u>Current assets</u>		
Inventories	50450	52166
Financial assets		
i. Trade receivables	14241	12657
ii. Cash and cash equivalents	2758	11368
iii. Bank balances other than (ii) above	87924	126399
iv. Loans	6653	6146
Tangible assets held for sale	2	414
Other current assets	5373	5468
Total current assets	167401	214618
Total Assets	273607	307294
EQUITY AND LIABILITIES		
<u>Equity</u>		
Equity share capital	8470	8470
Reserves and Surplus	177829	212222
Total Equity	186299	220692
<u>Liabilities</u>		
<u>Non-current liabilities</u>		
Financial liabilities		
i. Borrowings	119	160
ii. Other financial liabilities	225	351
Provisions	30322	28390
Other non-current liabilities	-	215
Total non-current liabilities	30666	29116

(Rs. lakhs)

Particulars	As at 30.09.2016	As at 31.03.2016
	Unaudited	
Current liabilities		
Financial liabilities		
i. Trade payables	28022	32309
ii. Other financial liabilities	19625	18468
Other current liabilities	2474	1891
Provisions	4563	4511
Income-tax liabilities (net)	1958	307
Total current liabilities	56642	57486
Total liabilities	87308	86602
Total equity and liabilities	273607	307294

Notes:

- Sales of the Pharmaceuticals business grew by 13% during the quarter ended 30th September 2016, as compared to the corresponding quarter in the previous year. The sales include a 3% growth arising from the vaccines Asset Sale Agreement with Novartis India that concluded as at 30th September, 2015. Sales and Net Profit have been adversely impacted by Government mandatory price cuts during the prior quarter.
- Employee benefits expense for quarter and six months ended 30th September, 2016 includes Rs. 376 lakhs towards actuarial loss on compensated absences.
- The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 27th October, 2016.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2016, the Company has for the first time adopted Ind AS with a transition date of April 1, 2015.
- The format for un-audited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
- The Ind AS compliant corresponding figures in the previous year have not been subjected to review/audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:

(Rs. lakhs)

Description	Corresponding 3 months ended 30.09.15	6 months ended 30.09.15	Year ended 31.03.2016
Net profit as per Indian GAAP	9605	18933	37521
Add/(Less) : Adjustments			
Provision for expected sales returns	(771)	(1485)	(3095)
Actual sales return adjusted against provision created	714	1520	3035
Actuarial gains passed through OCI	-	-	(30)
Share based payments - revaluation	(20)	-	-
Deferred Tax impact on Ind AS adjustments	27	(12)	32
Net profit as per Ind AS	9555	18956	37463
Other comprehensive income, net of income tax	-	-	20
Total comprehensive income for the period	9555	18956	37483

- The reconciliation of Equity reported in accordance with Indian GAAP to Equity in accordance with Ind AS is given below:

(Rs. lakhs)

Description	As on 31.03.2016
Equity as per Indian GAAP	171715
Add/(Less) : Adjustments	
Proposed dividend on equity shares reversed to retained earnings	50973
Provision for expected sales returns	(3095)
Deferred Tax impact on Ind AS adjustments	1099
Equity as per IND AS	220692

- The statutory auditors have carried out a limited review of the standalone results for the quarter ended 30th September, 2016.

By Order of the Board

Annaswamy Vaidheesh
Managing Director
DIN: 1444303

27th October, 2016